This case comes from a public McKinsey and Company article on chemical pricing, and Minerva Advisor treats it purely as a capability validation exercise. This is an independent teaching simulation, not real client correspondence, and not reviewed, endorsed, sponsored, certified, or commissioned by McKinsey and Company in any way. The proof boundary is strict: the system only sees facts that existed at the moment of decision. Anything published later in the article about the eventual solution or its results is deliberately held out, so we can verify Minerva's reasoning without letting it see the answer first.

The decision situation: a multinational chemical company manages thousands of products and tens of thousands of customers. Most pricing has relied on uniform, mass pricing rules, which drives away good customers with unnecessarily high prices while missing revenue from customers willing to pay more. Technology can generate more granular pricing recommendations, but frontline sales teams understand customer and market risk that no algorithm sees on its own. The Chief Commercial Officer must decide whether to test a combined approach, analytics recommendations paired with frontline review, on a small group of products and customers before touching pricing company-wide.

Minerva's work leaves a five-item receipt, not a single polished paragraph. It checks the source boundary, so no future facts leak in. It maps actors and events, separating pricing, sales, and customers. It separates established facts from inference. It builds a structured option comparison. And it runs an adversarial challenge against its own reasoning. Each of these five items is inspectable on its own, which is what makes the output auditable rather than just persuasive.

What we actually know: mass pricing is provably overpricing some customers and underpricing others, and that gap is destroying value on both sides. What we do not know is just as important. It is unknown whether frontline overrides of the analytics recommendations are reliable and well-documented, and it is unknown whether churn during any pilot would come from pricing changes, from service issues, or from competitive moves. Minerva treats those as separate, unresolved variables rather than assuming they cancel out.

The strongest challenge to trusting a pilot outright: frontline overrides could simply mask analytics failures instead of correcting them, because discount rationale today is unstructured and untraceable. Pilot results might also reflect one segment's price sensitivity rather than a generalizable pattern, and observed churn could stem from service or competitive factors that have nothing to do with price. The reversal condition is precise: before anyone trusts pilot outcomes to expand or halt the program, there must be a traceable-reasons codebook and a method for separating churn causes. Without that, the comparison cannot be validly interpreted.

One fact was deliberately held out of Minerva's view: what the company actually did later, building a unified data and analytics engine that let frontline staff adjust churn risk case by case inside one integrated validation system, and the published result, a three to seven percent increase in return on sales across seven countries. That published answer stayed isolated until after Minerva produced its own recommendation, so the reasoning could be checked against reality rather than reverse-engineered from it.

Three advisor personas cross-check the same judgment from different angles. Marcus reframes what the real decision actually is, beyond the surface framing of humans versus algorithms. Sofia models frontline bargaining power and what the organization would learn over time. Evelyn stress-tests the evidence and challenges any premature commitments. All three converge on the same conclusion: run a pilot only once the data conditions needed to explain outcomes are actually in place.

The executive response is not passive. The Chief Commercial Officer's condition for entering the Decision Room is a pilot that is stoppable and explainable, with defined review authority, clear stop conditions, and success metrics set in advance. Minerva's recommendation only becomes direction after that human confirmation. The system provides judgment; it does not sign on the executive's behalf.

Two executable options reach the table. One preserves frontline veto power but requires structured, traceable reasons for every override. The other runs parallel test groups, which sharpens the comparison but raises sample size and account risk. Each option is shown with its expected gain, its cost, and its reversibility, so the executive can see directly whether adding human judgment changes the recommendation itself, not just the wording around it.

The committed action, agreed this week: select one or two product lines and a set of noncritical accounts with tolerable churn risk, jointly owned by the commercial lead, pricing, and regional sales. Their job is to define the pilot segment, the review-authority rules, the stop conditions, and the success metrics before any company-wide rollout decision is made.

On this actual run, Minerva Advisor used four model calls, delivered its first decision in 15.204 seconds, and completed the full analysis in 24.123 seconds, passing both the thirty-second first-decision threshold and the forty-five-second complete-result threshold. Internal quality checks scored ten out of ten. This is product-evaluation evidence from a controlled test case, not a customer outcome, and it does not represent real chemical pricing changes, real churn, or real return-on-sales results at any company.